bf/NASDAQ:PTGX_icon.png

NASDAQ:PTGX

Protagonist Therapeutics Inc.

  • Stock

USD

Last Close

79.78

06/11 21:01

Market Cap

2.04B

Beta: 1.95

Volume Today

739.46K

Avg: 1.73M

PE Ratio

−11.44

PFCF: −12.63

    Description

    Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary...Show More

    Earnings

    Earnings per Share (Estimate*)

    -11232018-11-062020-05-072022-02-282023-08-032024-11-07

    Revenue (Estimate*)

    50M100M150M200M250M2018-11-062020-05-072022-02-282023-08-032024-11-07

    *Estimate based on analyst consensus